focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.50
Ask: 4.50
Change: 0.49 (13.96%)
Spread: 1.00 (28.571%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Proteome Sciences says San Diego lab now fully operational

Tue, 02nd Jan 2024 10:52

Proteome Sciences PLC - London-based protein-focused drug development services provider - Completes installation and setup of equipment in its new lab in San Diego, California. The lab is now fully operational. Back in May, Proteome had announced it was expanding its proteomics services to the US. Says that the lab is "well placed to serve demand from a growing number of US customers looking to outsource proteomics projects to underpin their drug development programmes".

Proteome Sciences US Inc President Ian Pike says: "I am delighted that we are able to open our doors to serve arguably the world's largest biotechnology hub in California. Providing easier access to our US customers and with innovations including TMTpro 32plex and single cell proteomics, delivered from both our dedicated laboratories in the US and Europe we are well set to continue our leading role in provision of tools, assays and services in proteomics research as it grows in importance to enhance pharmaceutical research and drug development."

Current stock price: 5.45 pence

12-month change: up 50%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Jun 2015 13:26

Proteome raises £2.5m from placing

Protein biomarker company Proteome Science has placed 13.86m shares at 18p each, raising £2.5m before expenses. The proceeds will be used to increase capacity and shorten lead times ensuring the company can continue to meet the significant increase in demand for its biomarker services from a growing

Read more
23 Jun 2015 06:59

Proteome Sciences Raises GBP2.5 Million In Share Placing (ALLISS)

Read more
29 May 2015 08:01

Proteome Sciences Says It Has Seen "Good Start" To 2015, Loss Widens

Read more
9 Mar 2015 08:40

Proteome Sciences Sees Good Start To 2015 On Contract Signings

Read more
12 Nov 2014 13:06

UK MIDDAY BRIEFING: RBS, HSBC Hit With Fines, Barclays Still In Talks

Read more
12 Nov 2014 12:02

UK WINNERS & LOSERS: G4S And Tullow Oil Lead FTSE 100 Gainers

Read more
12 Nov 2014 12:00

Proteome slides after warning on revenues

Shares in Proteome fell sharply on Wednesday after the group warned its revenue for the current year will be lower than market expectations and "somewhat" lower than the revenues achieved in 2013. The protein biomarker group explained that it had seen a continuation of the previously flagged delay t

Read more
12 Nov 2014 09:27

Proteome Says Revenue Will Not Meet Market Expectations

Read more
30 Sep 2014 09:41

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Read more
26 Sep 2014 07:21

UK MORNING BRIEFING: De La Rue, Shanks Issue Profit Warnings

Read more
26 Sep 2014 07:03

Proteome Sees "Excellent" Toxicity Test Results For Alzheimer's Drugs

Read more
25 Sep 2014 15:29

Proteome Sciences wins $2m biomarker deal

teerngasAIM biotech Proteome Sciences has been signed up to provide to develop diagnostic products for Alzheimer's disease group Genting TauRx Diagnostic, worth $2m in upfront and milestone payments. Proteome's biomarker services division will analyse blood samples from patients enrolled in a phase

Read more
25 Sep 2014 12:15

REPEAT: UK MIDDAY BRIEFING: Glaxo Appoints Philip Hampton As Next Chairman

Read more
25 Sep 2014 12:09

UK MIDDAY BRIEFING: Glaxo Appoints Ex-RBS Head As Non-Exec Chairman

Read more
25 Sep 2014 11:43

UK WINNERS & LOSERS: 5G Deal Boosts Vodafone Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.